RBC Capital Maintains Outperform on Verrica Pharmaceuticals, Lowers Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza maintains an Outperform rating on Verrica Pharmaceuticals but lowers the price target from $13 to $11.
October 04, 2024 | 3:56 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
RBC Capital's analyst Gregory Renza continues to rate Verrica Pharmaceuticals as Outperform, but reduces the price target from $13 to $11, indicating a more cautious outlook.
The Outperform rating suggests continued confidence in VRCA's potential, but the lowered price target reflects a tempered expectation of its short-term performance. This mixed signal may lead to neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100